Zenas BioPharma, Inc.
Zenas BioPharma, Inc. (ZBIO): 5 pipeline candidates · 6 upcoming catalysts · ~28 mo cash runway · 10 clinical trials. Updated within the last hour.
BioSniper Score
6-factor signal · derived from public data
28.4 months
D/E 1.23 · 0% dilution
Lead: Phase 3
5 candidates
6 upcoming, next in ~12d
17 buys · 0 sells (180d)
A transparent, data-derived signal for Zenas BioPharma, Inc.across cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
$1.2B
Cash
$500.2M
Quarterly Burn
$75.2M
Runway
28.4 mo
Revenue
—
Cash Runway vs Catalysts
A catalyst falls after projected cash runway — potential financing / dilution risk before it hits.
Pipeline (5 candidates)
| Drug | Phase |
|---|---|
| obexelimab | Phase 2 |
| orelabrutinib | Phase 3 |
| zb001 | Phase 1 |
| zb002 | Phase 1 |
| zb004 | Phase 1 |
Upcoming Catalysts (6)
Clinical data readout — efficacy/safety results are a high-impact catalyst.
Clinical data readout — efficacy/safety results are a high-impact catalyst.
68.6% historical Phase 3 primary-endpoint success rate (n=363)
Clinical data readout — efficacy/safety results are a high-impact catalyst.
Clinical data readout — efficacy/safety results are a high-impact catalyst.
68.6% historical Phase 3 primary-endpoint success rate (n=363)
Clinical data readout — efficacy/safety results are a high-impact catalyst.
68.6% historical Phase 3 primary-endpoint success rate (n=363)
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
136
Total value held
$859.9M
| Holder | Shares | Value |
|---|---|---|
| fmr llc | 9,082,000 | $177.6M |
| enavate sciences gp, llc | 3,919,159 | $76.6M |
| federated hermes, inc. | 3,127,031 | $61.1M |
| polar capital holdings plc | 2,548,444 | $49.8M |
| vanguard capital management llc | 2,490,782 | $48.7M |
| blackrock, inc. | 2,037,548 | $39.8M |
| nvp associates, llc | 1,838,482 | $35.9M |
| alliancebernstein l.p. | 897,321 | $32.6M |
| state street corp | 1,470,923 | $28.8M |
| wellington management group llp | 1,246,053 | $24.4M |
Showing top 10 of 136 institutional holders of Zenas BioPharma, Inc.. Sign up for the full 13F holder list and quarter-by-quarter ownership history.
Frequently asked questions
How many drug candidates are in Zenas BioPharma, Inc.'s pipeline?
Zenas BioPharma, Inc. (ZBIO) has 5 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.
What is Zenas BioPharma, Inc.'s lead drug candidate?
Zenas BioPharma, Inc.'s most advanced tracked candidate is obexelimab (Phase 2) for Warm Autoimmune Hemolytic Anemia; IgG4 Related Disease; Relapsing Multiple Sclerosis.
What is Zenas BioPharma, Inc.'s next catalyst?
Zenas BioPharma, Inc.'s next tracked catalyst is a Phase2_Topline event — "Phase 2 Readout: obexelimab" — expected June 30, 2026.
What is Zenas BioPharma, Inc.'s cash runway?
Based on its most recent reported cash balance and quarterly burn rate, Zenas BioPharma, Inc. has approximately 28.4 months of cash runway.
What is Zenas BioPharma, Inc.'s market capitalization?
Zenas BioPharma, Inc.'s market capitalization is approximately $1.2B.
Get the full picture on Zenas BioPharma, Inc.
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.